Aetna restricts use of anemia drugs

It's an anemia-drug pile-on: Aetna has tightened up its reimbursement rules for Aranesp, Epogen, and Procrit--and analysts believe it will be the first of many private insurers to make the move. Medicare restricted dosages in July after evidence surfaced that higher dosages could cause severe heart problems.

While Aetna's new policy isn't as restrictive as Medicare's, it is limiting. It requires patients to have low hemoglobin before getting the drug. And the insurer says it doesn't plan to back off from the change even if members balk. Earlier this summer, Blue Shield of California tried to restrict the drugs' dosages but changed its mind soon after when members complained.

If more private insurers follow Medicare's example, Amgen and Johnson & Johnson could suffer badly. Amgen's Aranesp sales fell 20 percent in the third quarter following Medicare's limitation.

- check out the report from the Los Angeles Times

Related Articles:
The top five layoffs of 2007: J&J | Amgen
FDA backs Medicare's anemia drug limits. Report
Medicare cap on anemia drugs could hammer Amgen. Report
Amgen, J&J win a round in anemia controversy. Report
New rules limit use of anemia drugs. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.